The biopharmaceutical industry is at an important crossroads in medical innovation. Drug developers must seize opportunity to find a more efficient, scalable way to recruit patients for clinical trials, or face costly delays in bringing new medicines to market. Amid increasing costs, declining productivity, decreasing pipelines and a host of other challenges plaguing the industry, the most significant problem in conducting clinical trials in the New Health is well documented: Sponsors and clinical research organizations (CROs) cannot recruit qualified patients fast enough.

This white paper examines the extraordinary opportunity for the biopharmaceutical industry in using data to drive more efficient patient recruitment strategies. In the paper, Dr. Christopher Cabell, Senior Vice President of Global Access to Patients at Quintiles, issues a challenge to the industry, government, technology providers, patients, payers and health care providers to collaborate and seize the opportunity that electronic health data holds for transforming patient recruitment.